1. 112 RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS). (April 2015) Authors: Garcia-Manero, G.; Fenaux, P.; Al-Kali, A.; Baer, M.R.; Sekeres, M.; Roboz, G.; Gaidano, G.; Scott, B.; Greenberg, P.; Platzbecker, U.; Steensma, D.P.; Kambhampati, S.; Kreuzer, K.A.; Godley, L.; Collins, R.; Atallah, E.; Azarnia, N.; Petrone, M.E.; Snyder, B.R.; Maniar, M. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S57 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 14 A PHASE 2, DOSE-FINDING STUDY OF SOTATERCEPT (ACE-011) IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) OR NON-PROLIFERATIVE CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) AND ANEMIA REQUIRING TRANSFUSION. (April 2015) Authors: Komrokji, R.; Garcia-Manero, G.; Ades, L.; Laadem, A.; Vo, B.; Prebet, T.; Stamatoullas, A.; Boyd, T.; Delaunay, J.; Steensma, D.P.; Sekeres, M.A.; Beyne-Rauzy, O.; Zou, J.; Attie, K.M.; Sherman, M.L.; Fenaux, P.; List, A.F. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S5 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 19 AN OBJECTIVE GENETIC ONTOGENY CLASSIFICATION IDENTIFIES TRUE BIOLOGICAL SECONDARY AML AMONG DE NOVO AML PATIENTS ≥60 YEARS OLD. (April 2015) Authors: Lindsley, R.C.; Mar, B.G.; Mazzola, E.; Grauman, P.G.; Lindeman, N.; Steensma, D.P.; DeAngelo, D.J.; Wadleigh, M.; Neuberg, D.; Stone, R.M.; Ebert, B.L. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S8 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 88 BONE MARROW BLAST (BMBL) RESPONSE CORRELATES WITH OVERALL SURVIVAL IN RIGOSERTIB-TREATED PATIENTS WITH HIGHER-RISK MDS AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS): A NEW RESPONSE CRITERION?. (April 2015) Authors: Silverman, L.R.; Fenaux, P.; Al-Kali, A.; Baer, M.R.; Sekeres, M.; Roboz, G.; Gaidano, G.; Scott, B.; Greenberg, P.; Platzbecker, U.; Steensma, D.P.; Kambhampati, S.; Kreuzer, K.A.; Godley, L.; Collins, R.; Atallah, E.; Navada, S.C.; Azarnia, N.; Garcia-Manero, G. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S44 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Undertreatment of Patients with Myelodysplastic Syndromes (MDS): Analysis of an Electronic Medical Records (EMR) Database Cohort of US MDS Patients. (April 2017) Authors: Steensma, D.P.; Scott, B.L.; Ma, X.; Fliss, A.; Kiselev, P.; Swern, A.S.; Sugrue, M.M. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S76 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗